{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:55:12Z","timestamp":1781654112951,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020152","name":"Madrigal Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020152","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.dld.2026.04.011","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:53:21Z","timestamp":1781178801000},"page":"935-942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Accuracy of the FIB-4 and LiverRisk score for use in primary risk assessment for liver fibrosis, and variation by age"],"prefix":"10.1016","volume":"58","author":[{"given":"Mary E.","family":"Rinella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0263-9384","authenticated-orcid":false,"given":"Yestle","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2253-6300","authenticated-orcid":false,"given":"Suneil","family":"Hosmane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5483-9571","authenticated-orcid":false,"given":"Jonathan J.","family":"Woolley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4634-8649","authenticated-orcid":false,"given":"Tom","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.dld.2026.04.011_bib0001","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.dld.2026.04.011_bib0002","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dld.2026.04.011_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13010135","article-title":"Integrated management of cardiovascular-renal-hepatic-metabolic syndrome: expanding roles of SGLT2is, GLP-1RAs, and GIP\/GLP-1RAs","volume":"13","author":"Theodorakis","year":"2025","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.dld.2026.04.011_bib0004","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic dysfunction-associated steatotic liver disease","volume":"393","author":"Targher","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.dld.2026.04.011_bib0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00535-023-02049-9","article-title":"Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography","volume":"59","author":"Kobayashi","year":"2024","journal-title":"J Gastroenterol"},{"issue":"1","key":"10.1016\/j.dld.2026.04.011_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/nu15010066","article-title":"The FIB-4 index predicts the development of liver-related events, extrahepatic cancers, and coronary vascular disease in patients with NAFLD","volume":"15","author":"Kamada","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.dld.2026.04.011_bib0007","doi-asserted-by":"crossref","DOI":"10.20517\/mtod.2024.42","article-title":"Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease","volume":"4","author":"Lonardo","year":"2024","journal-title":"Metabolism and Target Organ Damage"},{"issue":"1","key":"10.1016\/j.dld.2026.04.011_bib0008","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/dsi23-0010","article-title":"Understanding the burden of nonalcoholic fatty liver disease: time for action","volume":"37","author":"Younossi","year":"2024","journal-title":"Diabetes Spectrum"},{"issue":"6","key":"10.1016\/j.dld.2026.04.011_bib0009","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cgh.2011.03.020","article-title":"Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008","volume":"9","author":"Younossi","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"17","key":"10.1016\/j.dld.2026.04.011_bib0010","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJMra2403308","article-title":"Noninvasive assessment of liver fibrosis","volume":"393","author":"Castera","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.dld.2026.04.011_bib0011","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.dld.2026.04.011_bib0012","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.dld.2026.04.011_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.101903","article-title":"Updated recommendations for the management of metabolic dysfunction-associated steatotic liver disease (MASLD) by the Latin American working group","volume":"30","author":"Diaz","year":"2025","journal-title":"Ann Hepatol"},{"issue":"6","key":"10.1016\/j.dld.2026.04.011_bib0014","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dld.2026.04.011_bib0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.04.011_bib0016","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.trsl.2020.03.008","article-title":"Sex related differences in the pathogenesis of organ fibrosis","volume":"222","author":"Garate-Carrillo","year":"2020","journal-title":"Transl Res"},{"key":"10.1016\/j.dld.2026.04.011_bib0017","doi-asserted-by":"crossref","DOI":"10.70322\/fibrosis.2024.10006","article-title":"Sex and gender differences in liver fibrosis: pathomechanisms and clinical outcomes","volume":"2","author":"Jamalinia","year":"2024","journal-title":"Fibrosis"},{"issue":"3","key":"10.1016\/j.dld.2026.04.011_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2024.101271","article-title":"Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021","volume":"7","author":"Feng","year":"2025","journal-title":"JHEP Reports"},{"issue":"10","key":"10.1016\/j.dld.2026.04.011_bib0019","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.dld.2026.04.011_bib0020","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"10406","key":"10.1016\/j.dld.2026.04.011_bib0021","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(23)01174-1","article-title":"Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study","volume":"402","author":"Serra-Burriel","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.04.011_bib0022","series-title":"National health and nutrition examination survey 2017-March 2020 - Data Documentation, codebook, and frequencies","year":"2022"},{"issue":"3","key":"10.1016\/j.dld.2026.04.011_bib0023","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1148\/radiol.2015150619","article-title":"Elastography assessment of Liver fibrosis: society of Radiologists in Ultrasound Consensus Conference Statement","volume":"276","author":"Barr","year":"2015","journal-title":"Radiology."},{"issue":"9","key":"10.1016\/j.dld.2026.04.011_bib0024","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000515","article-title":"Comparison of blood-based liver fibrosis scores in the Mount Sinai Health System, MASLD Registry, and NHANES 2017-2020 study","volume":"8","author":"Chen","year":"2024","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.dld.2026.04.011_bib0025","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1053\/j.gastro.2024.03.017","article-title":"Metabolic dysfunction-associated fibrosis 5 (MAF-5) score predicts liver fibrosis risk and outcome in the general population with Metabolic dysfunction","volume":"167","author":"van Kleef","year":"2024","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.dld.2026.04.011_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2025.102512","article-title":"Diagnostic accuracy of the LiverRisk score to detect increased liver stiffness among a United States general population and subgroups","volume":"15","author":"van Kleef","year":"2025","journal-title":"J Clin Exp Hepatol"},{"issue":"6","key":"10.1016\/j.dld.2026.04.011_bib0027","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.medj.2024.03.003","article-title":"LiverRisk score: an accurate, cost-effective tool to predict fibrosis, liver-related, and diabetes-related mortality in the general population","volume":"5","author":"Liu","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.dld.2026.04.011_bib0028","series-title":"Brief overview of sample design, nonresponse bias assessment, and analytic guidelines for nhanes august 2021-August 2023","year":"2024"},{"key":"10.1016\/j.dld.2026.04.011_bib0029","unstructured":"National Center for Health Statistics. National Health and Nutrition Examination Survey: analytic Guidelines, 2011-2014 and 2015-2016. December 14, 2018. Available at: https:\/\/wwwn.cdc.gov\/nchs\/data\/nhanes\/analyticguidelines\/11-16-analytic-guidelines.pdf."},{"key":"10.1016\/j.dld.2026.04.011_bib0030","author":"Moraes Tsujimoto"},{"key":"10.1016\/j.dld.2026.04.011_bib0031","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1475-2840-13-83","article-title":"Low sensitivity of the metabolic syndrome to identify adolescents with impaired glucose tolerance: an analysis of NHANES 1999-2010","volume":"13","author":"DeBoer","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.dld.2026.04.011_bib0032","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1471-2458-10-304","article-title":"Low level exposure to cadmium increases the risk of chronic kidney disease: analysis of the NHANES 1999-2006","volume":"10","author":"Ferraro","year":"2010","journal-title":"BMC Public Health"},{"issue":"9616","key":"10.1016\/j.dld.2026.04.011_bib0033","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(08)60418-3","article-title":"Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort","volume":"371","author":"Gaziano","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.dld.2026.04.011_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097865","article-title":"Evaluation of Finnish Diabetes Risk Score in screening undiagnosed diabetes and prediabetes among U.S. adults by gender and race: NHANES 1999-2010","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.dld.2026.04.011_bib0035","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/sim.6405","article-title":"Estimation of ROC curve with complex survey data","volume":"34","author":"Yao","year":"2015","journal-title":"Stat Med"},{"issue":"11","key":"10.1016\/j.dld.2026.04.011_bib0036","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012799","article-title":"STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration","volume":"6","author":"Cohen","year":"2016","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.dld.2026.04.011_bib0037","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1186\/s12889-022-13724-6","article-title":"LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries","volume":"22","author":"Graupera","year":"2022","journal-title":"BMC Public Health"},{"issue":"2","key":"10.1016\/j.dld.2026.04.011_bib0038","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jceh.2022.11.014","article-title":"Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of nonalcoholic fatty Liver disease (NAFLD)","volume":"13","author":"Duseja","year":"2023","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2026.04.011_bib0039","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: october 2024 updates to AASLD Practice Guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.dld.2026.04.011_bib0041","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/hep.27978","article-title":"Toward a more accurate estimate of the prevalence of hepatitis C in the United States","volume":"62","author":"Edlin","year":"2015","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.dld.2026.04.011_bib0042","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","article-title":"Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis","volume":"22","author":"Noureddin","year":"2024","journal-title":"Clinical Gastroenterology and Hepatology"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826007188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826007188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:22:36Z","timestamp":1781652156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865826007188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1590865826007188"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.04.011","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accuracy of the FIB-4 and LiverRisk score for use in primary risk assessment for liver fibrosis, and variation by age","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}